Articles

Cardinal Health’s stock falls on mixed quarterly results

Cardinal Health’s shares fell premarket Thursday after the company reported mixed quarterly results but raised its full-year profit outlook.

Corporate insiders are on a buyers’ strike — signaling more downward pressure on stocks

Executives in the know aren’t biting at discounted share prices.

Peloton replaces CEO after 90% stock slide during his tenure, plans more layoffs

Barry McCarthy is stepping down as Peloton’s CEO, the connected-fitness company announced on Thursday morning.

Highly ranked manager who bet on Mag 7 giants looks to these second-order winners from AI

The MainStay Winslow Large Cap Growth fund owes a lot of its returns to Big Tech. Co-portfolio manager Justin Kelly is hot on the hunt for new winners. Here are some ideas.

With more of us living longer, traditional retirement plans just won’t cut it

Whatever your age, you need to invest more in your future to ensure you age well.

My grandmother’s house was split between her 10 kids almost 50 years ago. How do we figure out the cost basis?

If the property has been held for a long time things can become complicated.

What if you could take your existing mortgage with you to a new house?

Here’s the key that could unlock the U.S. housing market for buyers and sellers.

Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech

Novartis on Thursday said it will pay up to $1.75 billion for a U.S. biotech focused on cancer.

Intel and Microsoft are on different paths to profit from AI. One will be right.

Tech giants’ recent earnings reveal a clear winner in market leadership and momentum.

We’re all paying a high price for letting corporations have free rein over us

Deliberately weakening social protections has created greater financial and economic insecurity.

Regeneron’s stock dips after earnings fall short of estimates

Regeneron Pharmaceuticals’ stock fell 2.6% premarket Thursday, after the drug company’s first-quarter profit and revenue fell short of analyst estimates.

Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch

Moderna on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine maker looks launch its second product in the U.S. later this year.
1 1,063 1,064 1,065 1,066 1,067 2,172